DexCom, Inc. reported a gross profit of $2.8 billion for 2024, a 15% increase from the previous year, despite a dip in gross profit margin due to supply chain issues. As a result, Wells Fargo and Canaccord Genuity have both lowered their price targets for DXCM. DexCom is also expanding its product line with Smart Basal and anticipates increased insurance coverage for type 2 diabetes, which could broaden its market.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Key facts: DexCom reports $2.8B profit; Wells Fargo cuts price target
DexCom, Inc. reported a gross profit of $2.8 billion for 2024, a 15% increase from the previous year, despite a dip in gross profit margin due to supply chain issues. As a result, Wells Fargo and Canaccord Genuity have both lowered their price targets for DXCM. DexCom is also expanding its product line with Smart Basal and anticipates increased insurance coverage for type 2 diabetes, which could broaden its market.